TABLE 1.
Variables | Overall cohort, n = 60 No. of patients (%) |
Local recurrence, n = 11 No. of patients (%)* |
Any disease recurrence, n = 25 No. of patients (%)* |
---|---|---|---|
Tumor variables | |||
Site | |||
Tongue | 38 (63) | 8 (21) | 17 (45) |
Floor of mouth | 9 (15) | 1 (11) | 5 (56) |
Retromolar trigone | 7 (12) | 2 (28) | 2 (29) |
Lower alveolar ridge | 4 (7) | 0 | 1 (25) |
Hard palate | 2 (3) | 0 | 0 |
T classification | |||
T1 | 27 (45) | 2 (7) | 9 (33) |
T2 | 16 (27) | 4 (25) | 8 (50) |
T3 | 6 (10) | 2 (33) | 2 (33) |
T4 | 11 (18) | 3 (27) | 6 (55) |
N classification | |||
N0 | 39 (65) | 5 (13) | 12 (31) |
N1 | 9 (15) | 2 (22) | 5 (56) |
N2 | 12 (20) | 4 (33) | 8 (67) |
AJCC stage | |||
I | 22 (37) | 1 (5) | 6 (27) |
II | 7 (11) | 1 (14) | 3 (43) |
III | 10 (17) | 2 (20) | 5 (50) |
IV | 21 (35) | 7 (33) | 11 (52) |
Treatment variables | |||
Neck dissection | |||
Not done | 23 (38) | 1 (4) | 7 (30) |
Done | 37 (62) | 10 (27) | 18 (49) |
Adjuvant therapy | |||
None | 41 (68) | 7 (17) | 15 (37) |
Radiotherapy | 10 (17) | 2 (20) | 5 (50) |
Chemoradiotherapy | 9 (15) | 2 (22) | 5 (56) |
Pathologic variables | |||
WPOI at interface | |||
Type 1 or 2 or 3 | 13 (22) | 0 | 1 (3) |
Type 4 | 26 (43) | 5 (19) | 11 (42) |
Type 5 | 21 (35) | 6 (29) | 13 (62) |
Perineural invasion | |||
Absent | 36 (60) | 5 (14) | 12 (33) |
Small nerves <1 mm | 17 (28) | 3 (18) | 8 (47) |
Large nerves ≥1 mm | 7 (12) | 3 (43) | 5 (71) |
LI at interface | |||
Little or none | 14 (32) | 4 (29) | 7 (50) |
Large patches | 27 (45) | 3 (11) | 9 (33) |
Continuous band | 19 (23) | 4 (21) | 9 (47) |
LVSI | |||
Absent | 52 (87) | 10 (19) | 22 (42) |
Present | 8 (13) | 1 (13) | 3 (36) |
Tumor grade | |||
Well differentiated | 11 (18) | 1 (9) | 1 (9) |
Moderately differentiated | 36 (60) | 5 (14) | 16 (44) |
Poorly differentiated | 13 (22) | 5 (38) | 8 (61) |
Margins after first resection | |||
Negative | 56 (93) | 11 (20) | 23 (41) |
Positive** | 4 (7) | 0 | 2 (50) |
Tumor depth | |||
<4 mm | 18 (30) | 0 | 6 (33) |
≥4 mm | 25 (42) | 5 (20) | 10 (40) |
Unknown | 17 (28) | 6 (35) | 9 (53) |
BGS risk category | |||
Low | 4 (7) | 0 | 0 |
Intermediate | 24 (40) | 2 (17) | 8 (33) |
High | 32 (53) | 9 (28) | 17 (53) |
Systemic variables | |||
Age | |||
Median (minimum-maximum) | 60 (23–85) | 56 (42–77) | 56 (23–78) |
Sex | |||
Female | 22 (37) | 5 (23) | 11 (50) |
Male | 38 (63) | 6 (16) | 14 (37) |
Comorbidity (ACE-27) | |||
None to mild (0–1) | 46 (77) | 7 (15) | 17 (37) |
Moderate to severe (2–3) | 14 (33) | 4 (29) | 8 (57) |
Immune compromise | |||
Absent | 49 (82) | 6 (12) | 17 (35) |
Present | 11 (18) | 5 (45) | 8 (73) |
Abbreviations: AJCC, American Joint Committee on Cancer; WPOI, worst pattern of invasion; LI, lymphocytic infiltrate at tumor/host interface; LVSI, lymphovascular space invasion; BGS, Brandwein–Gensler score; ACE-27, Adult Comorbidity Evaluation-27 in which comorbidity is graded as none (grade 0), mild (grade 1), moderate (grade 2), and severe (grade 3).
The denominator used for calculation of percentage is the number from the column “overall cohort.”
All were negative after re-resection.